- ST Pharm and Quantoom Biosciences have announced an extended collaboration to accelerate the development and manufacturing of RNA-based vaccines and therapeutics.
- The collaboration includes a supply agreement for ST Pharm’s proprietary 5’-capping reagent, SmartCap®, and aims to enhance global RNA manufacturing capabilities.
ST Pharm and Quantoom Biosciences have announced an extended collaboration to advance the development and manufacturing of RNA-based vaccines and therapeutics. This partnership integrates the complementary strengths of both companies to enhance the global supply of critical RNA manufacturing technologies. A key component of the collaboration is the initial supply agreement for ST Pharm’s proprietary 5’-capping reagent, SmartCap®.
The collaboration is designed to leverage the advanced RNA technologies developed by both companies, providing a more robust and flexible RNA manufacturing ecosystem. ST Pharm, a CDMO specializing in RNA technology, will benefit from insights into Quantoom’s Ntensify mRNA production processes. In return, Quantoom will gain access to ST Pharm’s advanced IVT-based mRNA-LNP platform, including novel capping and formulation reagents.
The partnership is expected to accelerate the development of innovative RNA-based therapies by combining the expertise and resources of both companies. Mooje Sung, CEO of ST Pharm, commented, “This collaboration represents a significant step forward in our mission to provide cutting-edge and competitive RNA technologies to the global market.”
José Castillo, CEO of Quantoom Biosciences, also expressed enthusiasm about the partnership, stating, “By securing access to ST Pharm’s unique technologies, we are empowering our clients with unparalleled flexibility and control over their mRNA production processes.”
Overview of outsourcing trends 
